1. Home
  2. AMCX vs FHTX Comparison

AMCX vs FHTX Comparison

Compare AMCX & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AMCX

AMC Networks Inc.

HOLD

Current Price

$8.66

Market Cap

362.6M

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$3.99

Market Cap

323.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCX
FHTX
Founded
1980
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Medicinal Chemicals and Botanical Products
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
362.6M
323.4M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
AMCX
FHTX
Price
$8.66
$3.99
Analyst Decision
Sell
Strong Buy
Analyst Count
4
8
Target Price
$7.33
$11.50
AVG Volume (30 Days)
391.3K
112.3K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
132.55
25.32
EPS
N/A
N/A
Revenue
$2,311,801,000.00
$30,909,000.00
Revenue This Year
N/A
$8.89
Revenue Next Year
N/A
$20.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.75
52 Week Low
$5.41
$3.27
52 Week High
$10.28
$6.95

Technical Indicators

Market Signals
Indicator
AMCX
FHTX
Relative Strength Index (RSI) 58.56 39.06
Support Level $7.62 $3.65
Resistance Level $8.95 $5.82
Average True Range (ATR) 0.42 0.26
MACD -0.02 -0.07
Stochastic Oscillator 64.70 31.25

Price Performance

Historical Comparison
AMCX
FHTX

About AMCX AMC Networks Inc.

AMC Networks owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Share on Social Networks: